Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by Boston VA Research Institute, Inc.
Sponsor:
Collaborators:
Celgene Corporation
Kansas City Veteran Affairs Medical Center
VA Pittsburgh Healthcare System
VA Greater Los Angeles Healthcare System
Michael Debakey Veterans Affairs Medical Center
Edward Hines Jr. VA Hospital
Information provided by (Responsible Party):
Nikhil Munshi, M.D., Boston VA Research Institute, Inc.
ClinicalTrials.gov Identifier:
NCT01380106
First received: June 22, 2011
Last updated: October 18, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)